<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798898</url>
  </required_header>
  <id_info>
    <org_study_id>ISCOLIM</org_study_id>
    <nct_id>NCT04798898</nct_id>
  </id_info>
  <brief_title>Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation</brief_title>
  <acronym>ISCOLIM</acronym>
  <official_title>Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and&#xD;
      improve survival for patients undergoing curative-intent surgery for colorectal liver&#xD;
      metastases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Median survival in each arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>One-year survival</measure>
    <time_frame>1 year</time_frame>
    <description>One-year survival in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two-year survival</measure>
    <time_frame>2 years</time_frame>
    <description>Two-year survival in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Three-year survival</measure>
    <time_frame>3 years</time_frame>
    <description>Three-year survival in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>1, 2, and 3 years</time_frame>
    <description>Recurrence rate at 1, 2, and 3 years follow-up</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Complications</measure>
    <time_frame>30-day postoperatively</time_frame>
    <description>Immediate postoperative complications (bleeding, surgical site infection, intraabdominal abscesses, bile leak)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Metastasis Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention (+RFA) arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative partial RFA necrosis in the liver metastasis followed by liver resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (-RFA) arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Liver resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RFA (radiofrequency ablation)</intervention_name>
    <description>Preoperative RFA-induced partial necrosis of the liver metastasis</description>
    <arm_group_label>Intervention (+RFA) arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with metachronous colorectal liver metastases planned for resection&#xD;
&#xD;
          -  At least one tumor size &gt;=3cm&#xD;
&#xD;
          -  Performance status 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Extrahepatic metastases&#xD;
&#xD;
          -  Other malignant diseases within 5 years prior to diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jakob Kirkegård, MD, PhD</last_name>
    <phone>+4524995027</phone>
    <email>jakob.kirkegaard@auh.rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hospital, Department of Surgery</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Jakob Kirkegård, MD, PhD</last_name>
      <email>jakob.kirkegaard@auh.rm.dk</email>
    </contact>
    <investigator>
      <last_name>Frank V Mortensen, MD, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jakob Kirkegård, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

